CDC Confirms Effectiveness of HPV Vaccine in Men
May 28, 2010
CDC's Advisory Committee on Immunization Practices (ACIP) has confirmed its earlier provisional advice on vaccinating boys against human papillomavirus.
The burden of HPV is heaviest on females, ACIP noted. Improving coverage in females ages 11-12 "could potentially be a more effective and cost-effective strategy than adding male vaccination," ACIP suggested.
Men who have sex with men (MSM) are at risk for conditions associated with HPV types targeted by Gardasil, ACIP said. MSM have a higher incidence of certain diseases and cancers including intraepithelial neoplasias, anal cancers, and genital warts. Gardasil reportedly is highly effective in preventing anal intraepithelial neoplasias in MSM, according to the update. However, clinical trial data for Gardasil among MSM were not available to ACIP before October, nor have they been fully reviewed by FDA, ACIP said.
The complete report, "FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP)," was published in Morbidity and Mortality Weekly Report (2010;59(20):630-632).
05.27.2010; Alice Park
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)